Me, the popular at-home genetic testing company, has helped millions of people uncover their family roots and health risks through DNA analysis. Experts fear as the company faces financial issues they ...
The future of 23andMe, a genetic testing company, is uncertain due to financial challenges and recent workforce reductions.
In the year since its hack, 23andMe has lost all of its value and most of its governing board — and somehow, things just keep ...
Me announces 40% workforce reduction and cancellation of therapeutic programs following year of security breaches and ...
Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.
Bryan Johnson [archival audio]: The only thing we can play is don't die, don't kill each other, don't ruin our biosphere, don ...
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
The genetic testing firm will also close its drug development arm. CEO Anne Wojcicki said the cuts are necessary to “focus on ...
and 23andMe has run out of runway: Substantial Doubt: Tuesday marked the fifth round of layoffs since the start of 2023, when ...
Home genetics company 23andMe continues to struggle as demand for casual gene tracing declines. On Monday, the company announced that it has decided on a restructuring ...
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...